Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast in Psoriatic Arthritis and Psoriasis (Skin and Synovial Tissue)
NCT02558361Phase 4Withdrawn
- Sponsor
- University of South Florida
- Start
- Apr 2016
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of apremilast in psoriatic arthritis (PsA) and psoriasis, sponsored by University of South Florida. Primary endpoint: Change in 32 gene products in synovial and skin samples at 3 months. Planned start Apr 2016; status: withdrawn.
02
Drugs
apremilast
03
Conditions
psoriatic arthritis (PsA)psoriasis
Beyond the preview
Go deeper on NCT02558361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02558361.